
Investor Webinar – Monday 2 February @ 11:30 AEDT

Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to invite shareholders and interested parties to an Investor Webinar on **Monday, 2 February 2026, at 11:30 am AEDT**.

Managing Director Tom Spurling will discuss Nova Eye Medical's quarterly results and iTrack Registry update.

Webinar Details

- **Date: Monday, 2 February 2026**
- **Time: 11:30 am AEDT**
- **Presenter: Tom Spurling, Nova Eye Medical Managing Director**
- **Registration Link:**

https://us02web.zoom.us/webinar/register/WN_DimdwfufS_G-qhWLNmrlFg

Participants will have the opportunity to submit questions before the webinar by emailing mflynn@nova-eye.com or during the live Q&A session.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

-ENDS-

For more information:

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com